WebJul 4, 2006 · Clinical or serological evidence of systemic illness including hepatitis B, hepatitis C or Human immunodeficiency virus (HIV) Bleeding disorder or a low platelet which do not allow vaccination into the muscle Had seizures in the past Febrile illness (axillary temperature ≥ 37.1°C) or acute illness on the day of inclusion Contacts and Locations WebNov 21, 2011 · Before the recommended dose will be decided OCV-501 will be subcutaneously administered once a week at the dose in the study 311-10-001. ... Patients who have participated in any other clinical trials , excluding the Study 311-10-001). Contacts and Locations. Go to
Study of 2 Doses of HRV Vaccine Given ... - ClinicalTrials.gov
WebThis randomized, controlled trial in Cuba shows that IPV is immunogenic and diminishes the excretion of oral poliovirus in the stool after challenge with oral poliovirus vaccine. WebMar 3, 2015 · By studying OPV transmission in this setting, we will be able to assess the impact of differing immunization status on OPV shedding and transmission. We will conduct our study in a relatively isolated and semi-urban municipality of Orizaba, Veracruz, Mexico. he norderney
Study of OCV-501 in Patients With Acute Myeloid Leukemia …
WebAug 31, 2005 · Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. WebApr 18, 2012 · Clinical study Clinical trial ClinicalTrials.gov identifier (NCT number) Collaborator Condition/disease Contact Country Cross-over assignment Data Monitoring Committee (DMC) Early Phase 1 (formerly listed as Phase 0) Eligibility criteria Enrollment Exclusion criteria Expanded access Expanded access status Expanded access type … WebOPV is an attenuated vaccine, produced by the passage of the virus through nonhuman cells at a sub physiological temperature, which produces spontaneous mutations in the viral genome. [56] Oral polio vaccines … henopa charleroi